Herantis Pharma Plc’s to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Herantis Pharma Plc

Company release 11 Jan 2021 at 09:00 am EET

Herantis Pharma Plc (“Herantis”), an innovative drug development company pioneering new disease modifying and regenerative biologic and gene therapies, announced today that Craig Cook, Chief Executive Officer of Herantis, will present at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

The video webcast presentation will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 ET / 13:00 EET / 12:00 CET. To access the live webcast of Herantis’ live presentation, please visit: https://journey.ct.events/view/df528583-fb16-4585-bf73-34528bf083d3

A replay of the webcast can be accessed for up to 90 days following the live presentation.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases, and break the boundaries of standard therapeutic approaches. Leveraging deep scientific brilliance in protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis is advancing a rich pipeline of regenerative biological and gene therapies for high impact diseases.  These include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. Lymfactin® VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases.  Herantis is pursuing disease modifying treatments that slow, stop, or even reverse the course of diseases, and bring much needed innovation to these underserved diseases.  The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.